Clinical Trials
133 trialsNCT03808610 2026-05-13
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03878199 2026-04-24
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Ohio State University Comprehensive Cancer Center
Phase 1/2 Terminated
NCT03150004 2026-03-30
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Medical College of Wisconsin
Phase 2 Terminated
NCT03913559 2026-02-12
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT03926624 2026-01-22
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Delta-Fly Pharma, Inc.
Phase 3 Terminated
NCT04240002 2026-01-05
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Astellas Pharma Inc
Phase 1/2 Terminated
NCT05361057 2025-12-05
Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Terminated
NCT00776373 2025-11-05
UPCC 25406
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT05712278 2025-09-12
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
Sanofi
Phase 1 Terminated
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT05032183 2025-08-11
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03724084 2025-06-18
Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT02420717 2025-06-08
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04752163 2025-05-23
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03765541 2025-04-10
DEXAML-03
University Hospital, Toulouse
Phase 3 Terminated
NCT04778410 2025-03-20
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
Gilead Sciences
Phase 2 Terminated
NCT04778397 2025-02-05
ENHANCE-2
Gilead Sciences
Phase 3 Terminated
NCT04914676 2025-01-16
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission
University of Florida
Phase 2 Terminated
NCT04029688 2024-12-20
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
Phase 1/2 Terminated
NCT04526795 2024-12-12
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05601466 2024-11-06
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Terminated
NCT05601830 2024-11-06
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Terminated
NCT03488225 2024-07-16
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04526288 2024-05-23
CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT04113616 2024-03-22
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Kartos Therapeutics, Inc.
Phase 1/2 Terminated
NCT04956042 2024-02-12
Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia
CicloMed LLC
Phase 1/2 Terminated
NCT01186328 2024-02-01
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Terminated
NCT05020665 2024-01-10
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
Kronos Bio
Phase 3 Terminated
NCT04196010 2023-12-28
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
University of Washington
Phase 1 Terminated
NCT03904251 2023-11-18
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT02520011 2023-11-15
Alvocidib Biomarker-driven Phase 2 AML Study
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT03969420 2023-11-09
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT02957032 2023-10-10
A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Philogen S.p.A.
Phase 1 Terminated
NCT00074165 2023-07-06
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00335140 2023-07-03
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT03634228 2023-06-15
Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03504410 2023-02-08
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
Cornerstone Pharmaceuticals
Phase 3 Terminated
NCT01005914 2023-01-06
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT04402723 2022-12-01
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Terminated
NCT03518112 2022-11-04
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03988205 2022-07-19
Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia
Medical College of Wisconsin
Phase 4 Terminated
NCT03850535 2022-06-21
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Hoffmann-La Roche
Phase 1/2 Terminated
NCT04326439 2022-06-15
AflacLL1901 (CHOA-AML)
Emory University
Phase 2 Terminated
NCT02043587 2022-05-02
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
University of California, San Diego
Phase 2 Terminated
NCT02927938 2022-04-21
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
Wake Forest University Health Sciences
Phase 3 Terminated
NCT01187810 2022-03-31
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
South Plains Oncology Consortium
Phase 1 Terminated
NCT01876953 2022-03-31
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1/2 Terminated
NCT02545283 2022-01-11
MIRROS
Hoffmann-La Roche
Phase 3 Terminated
NCT03519984 2021-11-30
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
University of Southern California
Phase 1 Terminated
NCT01246752 2021-10-29
AML
University Hospital Carl Gustav Carus
Phase 3 Terminated